Therefore, the majority of patients who developed rhabdomyolysis were treated for STS (n = 65) at the dose approved for this indication 1.5 mg/m2 every 3 weeks (q3wk), followed by patients treated for ovarian cancer (n = 6), which is the second approved indication at the corresponding dose and schedule 1.1 mg/m2 q3wk. Here, STS is linked to ovarian cancer.